Genmab — Februar 2019
-
De må ikke kigge længere frem over næsen, end matematikken kan forsvare. Det kaldes forvaltning og ikke investering.
-
Matematik er, med det flotte fundament vi får tegnet, ikke anvendelig til Genmab
-
Mht netop Novod, er jeg 99 på at det er Jesper Ilsø der har skrevet om Genmab det sidste halvandet år, og Novod der skriver under - måske
-
Did anyone post the transcript yet? https://finance.yahoo.com/news/edited-transcript-gen-co-earnings-024120545.html
-
Er dette ikke lidt tydeligere end hvad vi ellers har hørt om Novo: In December 2017,
the collaboration was expanded to include an additional five potential target pair combinations and three commercial license options + yderlighere milestone i december -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind